Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043
You may also be interested in...
Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit
Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business
Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit
Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business
Urologix March Stock Price Gain Propelled By BPH Systems, Disposables
Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month